Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could tame tough eczema in phase 2 trial

NCT ID NCT07167758

Ongoing Disease control Sponsor: Triveni Bio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called TRIV-509 in 95 adults with moderate to severe atopic dermatitis (eczema). Participants receive four doses of either TRIV-509 or a placebo, then switch to the other group. The goal is to see if TRIV-509 improves eczema symptoms and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TRIV-509 (an experimental drug given as a shot under the skin)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe eczema that is not well controlled by current therapies.
What could go wrong
This is an early Phase 2a study with only 95 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

  • Triveni Bio Site #1

    Camp Hill, Pennsylvania, 17011, United States

  • Triveni Bio Site #10

    South Bend, Indiana, 46617, United States

  • Triveni Bio Site #11

    Fountain Valley, California, 17271, United States

  • Triveni Bio Site #12

    Niagara Falls, Ontario, L2H 1H5, Canada

  • Triveni Bio Site #13

    Ajax, Ontario, L1S 7K8, Canada

  • Triveni Bio Site #15

    North York, Ontario, M2N 3A6, Canada

  • Triveni Bio Site #16

    Bellaire, Texas, 77401, United States

  • Triveni Bio Site #17

    Newmarket, Ontario, L3Y 5G8, Canada

  • Triveni Bio Site #18

    Kyiv, 01135, Ukraine

  • Triveni Bio Site #21

    Prague, 11000, Czechia

  • Triveni Bio Site #22

    Ostrava, 70200, Czechia

  • Triveni Bio Site #23

    Prague, 15000, Czechia

  • Triveni Bio Site #24

    Chorzów, Silesian Voivodeship, 41-500, Poland

  • Triveni Bio Site #25

    Katowice, Silesian Voivodeship, 4-600, Poland

  • Triveni Bio Site #26

    Poznan, Wielkopolska, 61-731, Poland

  • Triveni Bio Site #27

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Triveni Bio Site #28

    Warsaw, Masovian Voivodeship, 00-872, Poland

  • Triveni Bio Site #29

    Sosnowiec, 41-200, Poland

  • Triveni Bio Site #3

    Miami, Florida, 33016, United States

  • Triveni Bio Site #30

    Poznan, Wielkopolska, 60-309, Poland

  • Triveni Bio Site #31

    Pardubice, 530 02, Czechia

  • Triveni Bio Site #33

    Wroclaw, Lower Silesian Voivodeship, 51-604, Poland

  • Triveni Bio Site #34

    Budapest, 1066, Hungary

  • Triveni Bio Site #37

    Prague, 13000, Czechia

  • Triveni Bio Site #38

    Pleven, 5800, Bulgaria

  • Triveni Bio Site #39

    Sofia, 1172, Bulgaria

  • Triveni Bio Site #4

    San Diego, California, 92123, United States

  • Triveni Bio Site #41

    Budapest, 1033, Hungary

  • Triveni Bio Site #43

    Debrecen, 4032, Hungary

  • Triveni Bio Site #5

    Dallas, Texas, 75230, United States

  • Triveni Bio Site #6

    Indianapolis, Indiana, 46250, United States

  • Triveni Bio Site #8

    Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.